Adagrasib CAS 2326521-71-3

Product Description:

Product Name: Adagrasib CAS 2326521-71-3

Synonyms:

2-[(2S)-4-[7-(8-chloronaphthalen-1-yl)-2-[[(2S)-1-methylpyrrolidin-2-yl]metho xy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-1-(2-fluoroprop-2-enoyl)piperazin-2-yl]acetonitrile;

Chemical & Physical Properties:

Appearance: white to Pale yellow powder

Assay: ≥ 99.0%

Boiling Point: 860.2℃

Density: 1.295g/cm3

Solubility: DMSO:1.0(Max Conc. mg/mL);1.7(Max Conc. mM)

Uses

Mirati Therapeutics produced the oral small-molecule KRAS inhibitor adagrasib (MRTX849). KRAS mutations make up about 85% of all RAS family mutations and are extremely prevalent in cancer. However, because of their strong affinity for GTP and GDP and because they lack a well defined binding site, the creation of KRAS inhibitors has proven difficult.

Adagrasib suppresses KRAS-dependent signaling by targeting the cysteine 12 residue of KRASG12C, one of the most prevalent KRAS mutations. Adagrasib demonstrated anti-tumor effects in a phase I/IB clinical research including patients with advanced solid tumors with mutations in KRASG12C (NCT03785249).



Phase II of the same trial demonstrated that adagrasib was effective without additional safety signals in patients with non-small-cell lung cancer (NSCLC) with a mutation in the KRASG12C gene. Adagrasib's new drug application (NDA) was approved by the FDA in February 2022 for the treatment of individuals with NSCLC that had previously received therapy and tested positive for KRASG12C.

Adagrasib obtained accelerated clearance from the FDA in December 2022 to treat KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) patients who have had at least one prior systemic therapy. Adagrasib is the second KRASG12C inhibitor that the FDA has approved, after sotorasib.

If you are interested in our products or have any questions, please feel free to contact us!

Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.